COMBINATION OF ACTIVE INGREDIENTS FOR THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER TYPE

摘要

in which Y is -CH- or -N- ; Rl is hydrogen, halogen, a CF3, (03-04) alkyl or (C1-C4) alkoxy group; R2 is hydrogen, halogen, hydroxyl, CF3, (C3-C4) alkyl or (C1-C4) alkoxy group; R3 and R4 each is hydrogen or (C1-C3) alkyl; X is (a) (C3-C6) alkyl; (C3-C6) alkoxy; (C3-C7) carboxyalkyl; (C1-C4) alkoxycarbonyl (C3-C6) alkyl; carboxyalkoxy,- or (C1-C4) alkoxycarbonyl (C3-C5) alkoxy; (b) a radical selected from (C3-C7) cycloalkyl, (C3- C7) cycloalkyloxy, (C3-C7) cycloalkylmethyl, (C3-C7) cycloalkylami.no and cyclohexenyl, said radical being optionally substituted by halogen, hydroxy, (C1-C4) alkoxy, carboxy, (C1-C4) alkoxycarbonyl, amino, mono or di- (C1-C4) alkylamino; or (c) a group selected from phenyl, phenoxy, phenylamino, N-(C1-C3) alkylphenylamino, phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsulfonyl, phenylsulfinyl or styryl, said phenyl group being optionally mono- or polysubstituted by halogen, CF3, (C1 c4) alkyl, (C1-C4) alkoxy, cyano, amino, mono- or di-(C1- C4) alkylamino, (C1-C4) acylamino, carboxy, (C1-C4) alkoxycarbonyl, aminocarbonyl, mono- or di-(C1-C4) alkylaminocarbonyl, amino (C1-C4) alkyl, hydroxy (€1-04) alkyl or halogeno (C1-C4) alkyl; optionally in the form of one of its pharmaceutically acceptable salts and a compound (b) active in the symptomatic treatment of DAT, optionally in the form of one of its pharmaceutically acceptable salts provided that when compound (a) is other than 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine or one of its pharmaceutically acceptable salts, compound (b) is an acetylcholinesterase inhibitor.